retatrutide nonalcoholic fatty liver disease nash trial Fatty Liver Disease and Fibrosis (NASH) Clinical Trial retatrutide nonalcoholic steatohepatitis nash trial

Polyunsaturated fatty acid receptors, GPR40 and GPR120, are expressed in the hypothalamus and control energy homeostasis and inflammation

In addition, liraglutide provided multiple additional benefits by reducing the incidence of hypoglycemia, lowering HbA1c and functioning through multiple mechanisms to better control multiple causes of MACE, such as blood lipids, BP as well as body weight (BW)

Eur J Pharmacol 991: 177305

Always consult with your healthcare provider before making changes to your medication.

PubMed, Kulanuwat, Sirikul, et al

If you were diagnosed with any of these health problems after taking a GLP-1 drug, our Ozempic lawyer in Charleston, South Carolina can help you seek compensation for its effects on your life